By Kathryn Calkins
Staff Writer

Xenometrix Inc. received a European patent that is said covers most gene expression profiles obtained by applying a chemical compound to a eukaryotic cell. The company believes that the patent covers a broad array of gene expression technologies and that many companies' drug discovery and optimization technologies could fall under this claim umbrella. However, companies focusing on drug discovery and optimization have assessed the patent differently.